These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27884921)

  • 1. Reply: 'More viral mutants, less HBsAg clearance? One size may not fit all'.
    Thompson A; Locarnini S; Revill P
    Gut; 2017 Aug; 66(8):1534-1535. PubMed ID: 27884921
    [No Abstract]   [Full Text] [Related]  

  • 2. More viral mutants, less HBsAg clearance? One size may not fit all.
    Tseng TC; Yang HC; Kao JH
    Gut; 2017 Jul; 66(7):1349. PubMed ID: 27797942
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to: "Serum HBsAg kinetics in clinical prediction".
    Brunetto M; Cornberg M; Chan HL
    J Hepatol; 2017 Jul; 67(1):193-194. PubMed ID: 28315711
    [No Abstract]   [Full Text] [Related]  

  • 4. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
    Flink HJ; van Zonneveld M; Hansen BE; de Man RA; Schalm SW; Janssen HL;
    Am J Gastroenterol; 2006 Feb; 101(2):297-303. PubMed ID: 16454834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.
    Chen J; Wang Z; Zhou B; Wang Y; Hou J
    Antivir Ther; 2012; 17(1):71-9. PubMed ID: 22267471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection.
    Liu J; Lee MH; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; Wang LY; You SL; Hsiao CK; Yang HI; Chen CJ
    J Hepatol; 2013 May; 58(5):853-60. PubMed ID: 23246508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
    Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
    Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a.
    Moucari R; Martinot-Peignoux M; Mackiewicz V; Boyer N; Ripault MP; Castelnau C; Leclere L; Dauvergne A; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
    Antivir Ther; 2009; 14(8):1183-8. PubMed ID: 20032548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.
    Boglione L; Cardellino CS; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
    J Med Virol; 2014 Nov; 86(11):1845-50. PubMed ID: 25131947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D.
    Kao CN; Su TH; Kao JH
    Aliment Pharmacol Ther; 2017 Feb; 45(3):480-481. PubMed ID: 28043091
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher detection rates of amino acid substitutions in HBV reverse transcriptase/surface protein overlapping sequence is correlated with lower serum HBV DNA and HBsAg levels in HBeAg-positive chronic hepatitis B patients with subgenotype B2.
    Su M; Xiang K; Li Y; Li Y; Deng J; Xu X; Yan L; Zhuang H; Li T
    Infect Genet Evol; 2016 Jun; 40():275-281. PubMed ID: 27006281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New amino acid changes in drug resistance sites and HBsAg in hepatitis B virus genotype H.
    Fernández-Galindo DA; Sánchez-Ávila F; Bobadilla-Morales L; Gómez-Quiróz P; Bueno-Topete M; Armendáriz-Borunda J; Sánchez-Orozco LV
    J Med Virol; 2015 Jun; 87(6):985-92. PubMed ID: 25732900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic hepatitis B in pregnant women: is hepatitis B surface antigen quantification useful for viral load prediction?
    Fujiko M; Chalid MT; Turyadi ; Ie SI; Maghfira ; Syafri ; Wahyuni R; Roni M; Patellongi I; Massi MN; Muljono DH
    Int J Infect Dis; 2015 Dec; 41():83-9. PubMed ID: 26571304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
    Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
    Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B viral factors and treatment responses in chronic hepatitis B.
    Lin CL; Kao JH
    J Formos Med Assoc; 2013 Jun; 112(6):302-11. PubMed ID: 23787007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously.
    Cheng HR; Kao JH; Wu HL; Chen TC; Tseng TC; Liu CH; Su TH; Chen PJ; Chen DS; Liu CJ
    Liver Int; 2014 Jul; 34(6):e71-9. PubMed ID: 24119014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
    Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G
    Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.